The commonly used diabetes drug exenatide or hopefully will help prevent or treat neurologic degener

Recently, in a study published in the international journal Brain, scientists from the University of London School and other organizations found that drugs for type 2 diabetes may reduce the risk of Parkinson's disease. In this paper, the researchers tested a drug called exenatide, which could be used as a potential treatment for Parkinson's disease in upcoming clinical trials. The relevant research results are suitable for the treatment of Parkinson's disease with diabetes drugs.

In this study, the researchers analyzed the medical history of 100288 patients with type 2 diabetes from the health improvement network database. Patients with type 2 diabetes generally have a higher risk of Parkinson's disease than those without type 2 diabetes, but the commonly used treatment drugs, GLP-1 agonists and DPP4 inhibitors, do not seem to reverse the increased risk of Parkinson's disease, the researchers said.

In addition, the probability of patients with Parkinson's disease (GLP-1) who were not likely to take GLP-1 in the next two years were less likely to be diagnosed with Parkinson's disease (GLP-1) than those who were not taking other drugs (GLP-1) within two years. This study further confirmed the results of phase III clinical trials of exenatide in the treatment of Parkinson's disease. Next, the researchers will recruit 200 patients with Parkinson's disease in the United States for further experiments. Previous studies have shown that patients with Parkinson's disease who receive exenatide once a week for a year may perform better in exercise tests than patients with placebo effects.

Researchers fordini said the findings increased the link between type 2 diabetes and Parkinson's disease, although researchers now know that most diabetics are not susceptible to Parkinson's disease. In addition, the researchers filled in evidence that exenatide may be beneficial in the prevention or treatment of Parkinson's disease, and that it can play a role according to the progress of patients' symptoms, rather than just reducing their symptoms. Naturally, this may require extensive clinical trials by later scientists.

In the end, the researchers suggest that clinicians may need to consider other risk factors for Parkinson's disease when taking drugs for patients with type 2 diabetes, but a large number of studies need to be done to determine its clinical application value.

For any requests of Peptide for research purpose, welcome to contact us. www.gtpeptide.com , sales1@gotopbio.com.